It seems Fauci knew what the Covid gene editing would do

Experimental mRNA HIV vaccine safe, shows promise in animals

An experimental HIV vaccine based on mRNA the same platform technology used in two highly effective COVID-19 vaccines shows promise in mice and non-human primates, according to scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. Their results, published in Nature Medicine, show that the novel vaccine was safe and prompted desired antibody and cellular immune responses against an HIV-like virus. Rhesus macaques receiving a priming vaccine followed by multiple booster inoculations had a 79% lower per-exposure risk of infection by simian-human immunodeficiency virus (SHIV) compared to unvaccinated animals. The research was led by Paolo Lusso, M.D., Ph.D., of NIAID's Laboratory of Immunoregulation, in collaboration with other NIAID scientists, investigators from Moderna, Inc. and colleagues at other institutions.

An experimental HIV vaccine based on mRNA the same platform technology used in two highly effective COVID-19 vaccines shows promise in mice and non-human primates, according to scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. Their results, published in Nature Medicine, show that the novel vaccine was safe and prompted desired antibody and cellular immune responses against an HIV-like virus. Rhesus macaques receiving a priming vaccine followed by multiple booster inoculations had a 79% lower per-exposure risk of infection by simian-human immunodeficiency virus (SHIV) compared to unvaccinated animals. The research was led by Paolo Lusso, M.D., Ph.D., of NIAID's Laboratory of Immunoregulation, in collaboration with other NIAID scientists, investigators from Moderna, Inc. and colleagues at other institutions.

"Despite nearly four decades of effort by the global research community,an effective vaccine to prevent HIV remains an elusive goal," said NIAID Director Anthony S. Fauci, M.D., chief of the Laboratory and a paper co-author. "This experimental mRNA vaccine combines several features that may overcome shortcomings of other experimental HIV vaccines and thus represents a promising approach."

The experimental vaccine works like mRNA COVID-19 vaccines. However, instead of carrying mRNA instructions for the coronavirus spike protein, the vaccine delivers coded instructions for making two key HIV proteins, Env and Gag. Muscle cells in an inoculated animal assemble these two proteins to produce virus-like particles (VLPs) studded with numerous copies of Env on their surface. Although they cannot cause infection or disease because they lack the complete genetic code of HIV, these VLPs match whole, infectious HIV in terms of stimulating suitable immune responses.

https://www.sciencedaily.com/releases/2021/12/211209124236.htm

Journal Reference:

Peng Zhang, Elisabeth Narayanan, Qingbo Liu, Yaroslav Tsybovsky, Kristin Boswell, Shilei Ding, Zonghui Hu, Dean Follmann, Yin Lin, Huiyi Miao, Hana Schmeisser, Denise Rogers, Samantha Falcone, Sayda M. Elbashir, Vladimir Presnyak, Kapil Bahl, Madhu Prabhakaran, Xuejun Chen, Edward K. Sarfo, David R. Ambrozak, Rajeev Gautam, Malcom A. Martin, Joanna Swerczek, Richard Herbert, Deborah Weiss, Johnathan Misamore, Giuseppe Ciaramella, Sunny Himansu, Guillaume Stewart-Jones, Adrian McDermott, Richard A. Koup, John R. Mascola, Andrés Finzi, Andrea Carfi, Anthony S. Fauci, Paolo Lusso. A multiclade env–gag VLP mRNA vaccine elicits tier-2 HIV-1-neutralizing antibodies and reduces the risk of heterologous SHIV infection in macaques. Nature Medicine, 2021; DOI: 10.1038/s41591-021-01574-5

Memology scientistific basis

Visuals increase attention; now science explains why

Chemical’s release in brain tied to processing of imagery, cells’ activation

Date:

December 17, 2021

Source:

University of Texas Health Science Center at San Antonio

Summary:

Scientists report that norepinephrine, a fundamental chemical for brain performance, is locally regulated in a brain region called the visual cortex.

Share:

FULL STORY

"Look at me!" we might say while attempting to engage our children. It turns out there is a neurochemical explanation for why looking at mom or dad actually helps kiddoes pay better attention

In a paper published Dec. 17 in the journal Science Advances, authors from The University of Texas Health Science Center at San Antonio (also referred to as UT Health San Antonio) report that norepinephrine, a fundamental chemical for brain performance, is locally regulated in a brain region called the visual cortex.

"Before our study, research suggested the possibility of local regulation of norepinephrine release, but it had never been directly demonstrated," said study senior author Martin Paukert, MD, assistant professor of cellular and integrative physiology at UT Health San Antonio. The work of the team, which included Shawn R. Gray, PhD, and Liang Ye, MD, from the Paukert lab and Jing Yong Ye, PhD, from the biomedical engineering department at The University of Texas at San Antonio, was supported by the Robert J. Kleberg, Jr. and Helen C. Kleberg Foundation, the National Institute of Mental Health (NIMH) and the National Institute on Alcohol Abuse and Alcoholism (NIAAA).

Norepinephrine is known to be involved in paying attention. "A certain amount of this chemical needs to be released for optimum brain performance and ability to pay attention," Dr. Paukert said. "So, if there is either too much of it or too little of it, it may affect how we process information."

Disease states in which norepinephrine is known to be altered include substance use disorders, Alzheimer's disease, post-traumatic stress disorder (PTSD) and attention-deficit/hyperactivity disorder (ADHD). In some substance use, Alzheimer's and ADHD, the release of norepinephrine is reduced, resulting in lower attention. In other substance use and PTSD, the level is too high.

The team's findings also extend to cells called astrocytes that function as helper cells in the brain and central nervous system.

"When a person makes a movement, such as turning the head to listen to a parent, and that is combined with visual stimulation, then more norepinephrine is released where visual information is processed," Dr. Paukert said. "Our second finding, also important, is that astrocytes can reliably detect the rate of norepinephrine release."

They are sensitive to it, in other words. Astrocytes alter their response accordingly, which is expected to change brain performance.

"Understanding norepinephrine release, its local regulation and the astrocyte response may represent a mechanism by which one could enhance sensory-specific attention," Dr. Paukert said. Research will continue in that direction.

https://www.sciencedaily.com/releases/2021/12/211217151933.htm

>>15236220

Oops didnt mean to post the tweets

You are a machine, you will live with nothing and be happy with it

Pioneering new technique to barcode cells

Date:

December 17, 2021

Source:

University of Exeter

Summary:

Scientists have developed a pioneering new technique to barcode individual cells more accurately and efficiently - which could help pave the way for quicker disease diagnosis.

Share:

FULL STORY

Scientists have developed a pioneering new technique to barcode individual cells more accurately and efficiently – which could help pave the way for quicker disease diagnosis.

A team of researchers from the Living Systems Institute at the University of Exeter has created a new method, that combines artificial intelligence with microfluidics, that can easily classify, sort and count individual cells.

The ground-breaking new technique allows scientists to carry out intricate and in-depth analysis of single cells, including mammalian cells, in real-time.

Previously, there have been no general methods to accurately sample and barcode isolated single cells without large wastage during the sampling process.

This new approach, however,allows scientists to barcode individual cells much more accurately and efficientlythan before to quantify their molecular make-up – a crucial development as disease often comes from the malfunction of a few cells.

The new technique could revolutionise the crucial early diagnosis of some of the most debilitating and life-threatening diseases, including cancer.

The study is published in the journal Advanced Materials Technologies.

Dr. Fabrice Gielen, principal investigator of the research group from the Living Systems Institute said: "With the technology we have developed, we have the opportunity to advance our understanding of the origin of differences observed between cells in a population.

"These differences are seen at the molecular level and are especially large during key cell stages such as differentiation into specialised cells, but can also be indicative of early cancer development.

"We have applied our tool for screening of thousands of single cells from real-time imaging data and efficiently barcode them with minimum cell waste.

"We are currently applying this tool to screen miniature in-vitro tumours formed from model neuroblastoma cells to understand why cancer progression appears to be highly unpredictable in clinical settings. This may lead to early diagnostics and the use of targeted therapeutics.

"Our technique being generic in scope, we also foresee plenty of further opportunities enabled by real-time image analyses such as the study of bacterial biofilm formation and the degradation of plastic microfibers by biocatalysts."

https://www.sciencedaily.com/releases/2021/12/211217102740.htm

Shark antibody-like proteins neutralize COVID-19 virus, help prepare for future coronaviruses

Date:

December 17, 2021

Source:

University of Wisconsin-Madison

Summary:

Small, unique antibody-like proteins known as VNARs derived from the immune systems of sharks can prevent the virus that causes COVID-19, its variants, and related coronaviruses from infecting human cells, according to a new study.

Small, unique antibody-like proteins known as VNARs derived from the immune systems of sharks - can prevent the virus that causes COVID-19, its variants, and related coronaviruses from infecting human cells, according to a new study publ Dec. 16.

The new VNARs will not be immediately available as a treatment in people, but they can help prepare for future coronavirus outbreaks. The shark VNARs were able to neutralize WIV1-CoV, a coronavirus that is capable of infecting human cells but currently circulates only in bats, where SARS-CoV-2, the virus that causes COVID-19, likely originated.

Developing treatments for such animal-borne viruses ahead of time can prove useful if those viruses make the jump to people.

"The big issue is there are a number of coronaviruses that are poised for emergence in humans," says Aaron LeBeau, a University of Wisconsin-Madison professor of pathology who helped lead the study. "What we're doing is preparing an arsenal of shark VNAR therapeutics that could be used down the road for future SARS outbreaks. It's a kind of insurance against the future."

LeBeau and his lab in the School of Medicine and Public Health collaborated with researchers at the University of Minnesota and Elasmogen, a biomedical company in Scotland that is developing therapeutic VNARs. The team published its findings in Nature Communications.

The anti-SARS-CoV-2 VNARs were isolated from Elasmogen's large synthetic VNAR libraries. One-tenth the size of human antibodies, the shark VNARs can bind to infectious proteins in unique ways that bolster their ability to halt infection.

"These small antibody-like proteins can get into nooks and crannies that human antibodies cannot access," says LeBeau. "They can form these very unique geometries. This allows them to recognize structures in proteins that our human antibodies cannot."

The researchers tested the shark VNARs against both infectious SARS-CoV-2 and a "pseudotype," a version of the virus that can't replicate in cells. They identified three candidate VNARs from a pool of billions that effectively stopped the virus from infecting human cells. The three shark VNARs were also effective against SARS-CoV-1, which caused the first SARS outbreak in 2003.

One VNAR, named 3B4, attached strongly to a groove on the viral spike protein near where the virus binds to human cells and appears to block this attachment process. This groove is very similar among genetically diverse coronaviruses, which even allows 3B4 to effectively neutralize the MERS virus, a distant cousin of the SARS viruses.

The ability to bind such conserved regions across diverse coronaviruses makes 3B4 an attractive candidate to fight viruses that have yet to infect people.

The 3B4 binding site is also not changed in prominent variations of SARS-CoV-2, such as the delta variant. This research was conducted before the omicron variant was discovered, but initial models suggest the VNAR would remain effective against this new version, LeBeau says….

https://www.sciencedaily.com/releases/2021/12/211217102915.htm

More fear mongering

https://twitter.com/JohnBasham/status/1473425204894441473?s=20

https://twitter.com/JohnRossomando/status/1470909290991042569?s=20

This wouldn’t surprise me

https://twitter.com/JackPosobiec/status/1473531499303550977?s=20

il Donaldo Trumpo

😂😂😂 https://t.co/xoOoK3tlu4

The most untrustworthy congressman talks about Manchin! Kek

https://twitter.com/PapiTrumpo/status/1473468625621237761?s=20

https://twitter.com/rising_serpent/status/1473471897367109636?s=20

>>15236543

I know!

Now do it WW

https://twitter.com/rising_serpent/status/1473120212916609024?s=20